Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KTTFS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
XMT-2056
|
|||||
| Synonyms |
XMT 2056; XMT2056
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 4 Indication(s)
HER2(+) breast cancer [ICD11:2C60-2C65]
Phase 1
HER2(+) colorectal cancer [ICD11:2B91]
Phase 1
HER2(+) gastric cancer [ICD11:2B72]
Phase 1
HER2(mu) non-small cell lung cancer [ICD11:2C25]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.